Abstract:BACKGROUND Acute liver failure (ALF) is a significant and complex hepatic insult that may rapidly progress to life-threatening conditions. Recently, menstrual blood stem cells (MenSCs) have been identified as a group of easily accessible mesenchymal stem cells with the advantages of non-invasive acquisition, low immunogenicity, a greater capacity of self-renewal and multi-lineage differentiation, making them promising candidates for stem cell-based therapy to revolutionize the treatment strategies for liver failure. AIM To investigate the therapeutic potential of MenSCs for treating ALF in pigs and to dynamically trace the biodistribution of transplanted cells. METHODS MenSCs were labeled in vitro with PKH26, a lipophilic fluorescent dye. The treatment group received immediate transplantation of PKH26-labelled MenSCs (2.5 × 106/kg) via the portal vein after D-galactosamine injection, and the control group underwent sham operation. The survival time, liver function, and hepatic pathological changes were compared between the two groups. Three major organs (liver, lungs and spleen) were extracted from animals and imaged directly with the In vivo Imaging System (IVIS) at the predetermined time points. The regions of interest were drawn to quantify the cell uptake in different organs. RESULTS The labelling procedure did not affect the morphology, viability or multipotential differentiation of MenSCs. Biochemical analysis showed that the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL) and prothrombin time (PT) measured at selected time points 24 h after transplantation were significantly decreased in the treatment group (P < 0.05). The survival time of ALF animals was prolonged in the treatment group compared with the control group (75.75 ± 5.11 h vs 53.75 ± 2.37 h, log rank, P < 0.001). The liver pathological tissue in the MenSC treatment group showed obviously increased numbers of remaining hepatocytes and a comparatively slight necrotic degree and area. In addition, the IVIS imaging revealed that PKH26-positive MenSCs were clearly retained in the liver initially and then diffused through the systemic circulation. Interestingly, the signal intensity in the liver increased obviously at 36 h, which corresponded to the biochemical result that liver function deteriorated most rapidly at 24 - 36 h. CONCLUSION Our study demonstrates the therapeutic efficacy and homing ability of transplanted MenSCs in a large animal model of ALF and suggests that MenSC transplantation could be a promising strategy for treating ALF.

Transcriptional profiling and hepatogenic potential of acute hepatic failure-derived bone marrow mesenchymal stem cells.

Acute Hepatic Failure-Derived Bone Marrow Mesenchymal Stem Cells Express Hepatic Progenitor Cell Genes

The preliminarily investigation of therapeutic effects of mesenchymai stem cells on rat fulminant hepatic failure

Committed-differentiation of Transplanted Bone Derived Mesenchymal Stem Cells and Their Potential to Amend Damaged Liver Functions: in Vivo Experiment with Mice

Improvement of mesenchymal stromal cells and their derivatives for treating acute liver failure

Therapeutic Potential of Menstrual Blood Stem Cells in Treating Acute Liver Failure

Amniotic Fluid-Derived Mesenchymal Stem Cells As A Novel Therapeutic Approach in the Treatment of Fulminant Hepatic Failure in Rats

Reconstruction of hepatic functions after bone marrow mesenchymal stem cells transplantation

Study on the therapy of hepatic failure using hepatocyte-like cells derived from bone marrow transplantation

The Effects of Conditioned Medium Derived from Mesenchymal Stem Cells Cocultured with Hepatocytes on Damaged Hepatocytes and Acute Liver Failure in Rats

Menstrual Blood-Derived Mesenchymal Stem Cells Differentiate into Functional Hepatocyte-Like Cells

Transcriptome Profiling Reveals Distinct Phenotype Of Human Bone Marrow Mesenchymal Stem Cell-Derived Hepatocyte-Like Cells

Human umbilical cord matrix stem cells efficiently rescue acute liver failure through paracrine effects rather than hepatic differentiation.

Current understanding of adipose-derived mesenchymal stem cell-based therapies in liver diseases

Porcine Adipose-Derived Mesenchymal Stem Cells Retain Their Stem Cell Characteristics and Cell Activities While Enhancing the Expression of Liver-Specific Genes after Acute Liver Failure

Adipose-derived Stem Cells Show Hepatic Differentiation Potential and Therapeutic Effect in Rats with Acute Liver Failure

Hepatic Differentiation Capability of Rat Bone Marrow-Derived Mesenchymal Stem Cells and Hematopoietic Stem Cells

Quantitative evaluation of human bone mesenchymal stem cells rescuing fulminant hepatic failure in pigs

Differentiation and Migration of Bone Marrow Mesenchymal Stem Cells Transplanted Through the Spleen in Rats with Portal Hypertension.

Comparative Study of in vitro Hepatic Differentiation Capability of Two Different Stem Cell Subsets Derived from Bone-marrow

Protein from acute liver failure rat liver Homogenate induce bone marrow stem cells differentiate into hepatocyte-like cells in vitro